AAAAAA

   
Results: 1-7 |
Results: 7
Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial
Authors: Ackerman, SJ Klumpp, TR Guzman, GI Herman, JH Gaughan, JP Bleecker, GC Mangan, KF
Citation: Sj. Ackerman et al., Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial, TRANSFUSION, 40(12), 2000, pp. 1457-1462
Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
Authors: Stadtmauer, EA O'Neill, A Goldstein, LJ Crilley, PA Mangan, KF Ingle, JN Brodsky, I Martino, S Lazarus, HM Erban, JK Sickles, C Glick, JH
Citation: Ea. Stadtmauer et al., Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer., N ENG J MED, 342(15), 2000, pp. 1069-1076
A rapid two-step method for elimination of bcl-2/IgH positive non-Hodgkin's lymphoma cells from human blood or marrow stem cells, employing immunomagnetic purging with streptavidin-coated ferrofluids
Authors: Mangan, KF Leonardo, J Mullaney, MT Terstappen, LWMM Rao, C Liberti, P
Citation: Kf. Mangan et al., A rapid two-step method for elimination of bcl-2/IgH positive non-Hodgkin's lymphoma cells from human blood or marrow stem cells, employing immunomagnetic purging with streptavidin-coated ferrofluids, CYTOTHERAPY, 1(4), 1999, pp. 287-293
Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial
Authors: Klumpp, TR Herman, JH Gaughan, JP Russo, RR Christman, RA Goldberg, SL Ackerman, SJ Bleecker, GC Mangan, KF
Citation: Tr. Klumpp et al., Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial, TRANSFUSION, 39(7), 1999, pp. 674-681
A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients
Authors: Shpall, EJ Wheeler, CA Turner, SA Yanovich, S Brown, RA Pecora, AL Shea, TC Mangan, KF Williams, SF LeMaistre, CF Long, GD Jones, R Davis, MW Murphy-Filkins, R Parker, WRL Glaspy, JA
Citation: Ej. Shpall et al., A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients, BLOOD, 93(8), 1999, pp. 2491-2501
Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients
Authors: Goldberg, SL Klumpp, TR Magdalinski, AJ Mangan, KF
Citation: Sl. Goldberg et al., Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients, J CL ONCOL, 16(12), 1998, pp. 3796-3802
Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study
Authors: Samlomski, WE Lew, D Kuebler, PJ Kolodziej, MA Medina, JE Mangan, KF Moore, DF Schuller, DE Ensley, JF
Citation: We. Samlomski et al., Evaluation of Tomudex in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group study, INV NEW DR, 16(3), 1998, pp. 271-274
Risultati: 1-7 |